Literature DB >> 2121398

Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy.

P Caron1, C Calazel, H J Parra, M Hoff, J P Louvet.   

Abstract

Thyroid function and lipid tests were measured in 29 premenopausal women with subclinical hypothyroidism. This group was compared with 41 euthyroid women matched for age and metabolic parameters. In basal condition there was no difference in thyroid hormone levels between the two groups except for TSH concentration (P less than 0.01). Total cholesterol, triglycerides and apolipoprotein (apo A1, A2, B) of women with subclinical hypothyroidism were not different from controls. HDL cholesterol was significantly decreased in subclinical hypothyroidism compared to the controls (P less than 0.01). With thyroxine therapy, normalization of serum TSH was associated with (1) no significant change in total cholesterol and triglycerides, (2) an increase of HDL cholesterol (P less than 0.01) and apoprotein A1 (P less than 0.05) levels. Total cholesterol/HDL cholesterol ratio was increased in subclinical hypothyroidism (P less than 0.01). During L-thyroxine therapy this ratio returned to normal value. Decreased HDL cholesterol concentration might cause coronary heart disease reported in women with subclinical hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121398     DOI: 10.1111/j.1365-2265.1990.tb03889.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  17 in total

1.  Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat.

Authors:  U M Kabadi; R Cech
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

2.  The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism.

Authors:  R Serter; B Demirbas; B Korukluoglu; C Culha; E Cakal; Y Aral
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

3.  Cost effectiveness of screening for subclinical hypothyroidism in the elderly. A decision-analytical model.

Authors:  M Bona; F Santini; G Rivolta; E Grossi; R Grilli
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

4.  Subclinical hypothyroidism and mortality in a large Austrian cohort: a possible impact on treatment?

Authors:  Florian Maria Kovar; I-Fei Fang; Thomas Perkmann; Helmuth Haslacher; Georg Slavka; Manuela Födinger; Georg Endler; Oswald F Wagner
Journal:  Wien Klin Wochenschr       Date:  2015-09-15       Impact factor: 1.704

5.  Metabolic syndrome prevalence in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters.

Authors:  M Erdogan; A Canataroglu; S Ganidagli; M Kulaksızoglu
Journal:  J Endocrinol Invest       Date:  2010-07-22       Impact factor: 4.256

6.  Natural course of subclinical hypothyroidism in Down's syndrome: prospective study results and therapeutic considerations.

Authors:  D Rubello; G B Pozzan; D Casara; M E Girelli; S Boccato; F Rigon; C Baccichetti; M Piccolo; C Betterle; B Busnardo
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

7.  Increased mean serum thyrotropin in apparently euthyroid hypercholesterolemic patients: does it mean occult hypothyroidism?

Authors:  D Pallas; D A Koutras; P Adamopoulos; P Marafelia; A Souvatzoglou; G Piperingos; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

Review 8.  Subclinical thyroid disease.

Authors:  J W Elte; A H Mudde; A C Nieuwenhuijzen Kruseman
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

9.  Thyroid antoantibodies and the response to thyrotropin releasing hormone in patients with subclinical hypothyroidism.

Authors:  O A Mojiminiyi; V Rege; J Bolodeoku; A H Wilcox; J L Barron
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

10.  Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment.

Authors:  F Monzani; P Del Guerra; N Caraccio; C A Pruneti; E Pucci; M Luisi; L Baschieri
Journal:  Clin Investig       Date:  1993-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.